Zobrazeno 1 - 10
of 350
pro vyhledávání: '"N, Frickhofen"'
Autor:
N. Frickhofen
Publikováno v:
Atemwegs- und Lungenkrankheiten. 42:318-323
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c41dc00c1890325707a253a901a0ddbd
https://doi.org/10.5414/atx02108
https://doi.org/10.5414/atx02108
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Annette Hasenburg, Gabriele Calaminus, Friedrich Kommoss, A. du Bois, Olaf Ortmann, M. Gebhardt, Daniel Fink, Felix Hilpert, P. Ortner, Diana Lüftner, W Meier, P. Piso, Joachim Weis, B. Radeleff, Klaus König, Dieter Grab, Edgar Petru, IB Runnebaum, N. Frickhofen, F. Grünwald, P. Harter, B. O. Maier, Sven Mahner, Jacobus Pfisterer, Norbert Arnold, C. Eggert, K. Lindel, Steffen Hauptmann, G. Emons, Uwe Wagner, A Reuß, Alexander Burges, Joachim Diebold, I. Weisse, Jalid Sehouli
Publikováno v:
Geburtshilfe und Frauenheilkunde. 73:874-889
2.1 Target audience The guideline was compiled with the aim of providing high-risk groups with advice on diagnostics, surgical and systemic therapy in early and advanced stages of disease together with the treatment of rare histological subtypes. A l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b8f15377be760e9a7368f06d5f884aef
https://doi.org/10.1055/s-0033-1350713
https://doi.org/10.1055/s-0033-1350713
Autor:
N. Frickhofen, Rudolf M. Huber, Marius Giurescu, Wilfried Eberhardt, Juergen R. Fischer, Daniel C. Christoph, Katrin Roth, Thomas Gauler, Christine Gonschorek
Publikováno v:
European Journal of Cancer. 49:2461-2468
Background Sagopilone (ZK219477) is a new and fully synthetic epothilone with activity against multi-drug resistant tumour cell lines. It has demonstrated clinical activity in several solid tumours like ovarian cancer and melanoma. Data about clinica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96dbb28ca16de730eed16abced6f7034
https://doi.org/10.1016/j.ejca.2013.03.029
https://doi.org/10.1016/j.ejca.2013.03.029
Autor:
Cornelius Kortsik, Cornelius F. Waller, Martin Reck, Martin Schuler, N. Frickhofen, Martin Sebastian, Gertraud Hanft, Gerd Munzert, Birgit Gaschler-Markefski, Joachim von Pawel, Holger Fritsch
Publikováno v:
Journal of Thoracic Oncology. 5:1060-1067
Objective To investigate the efficacy, safety, and pharmacokinetics of two dosing schedules of BI 2536, a novel polo-like kinase-1 inhibitor, in patients with relapsed stage IIIB/IV non-small cell lung cancer. Methods Ninety-five patients were random
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81a321e2365d0644ad36a56ad54a0aad
https://doi.org/10.1097/jto.0b013e3181d95dd4
https://doi.org/10.1097/jto.0b013e3181d95dd4
Autor:
Michael Thomas, Silke Neumann, M Thomer, Walburga Engel-Riedel, Juergen R. Fischer, W. Eberhardt, Georgios Stamatis, Thomas Graeter, Martin Reck, Jens Kollmeier, N. Frickhofen, P De Leyn, C Schuhmann, Michael Kreuter, Johan Vansteenkiste, Monika Serke, Frank Griesinger, Heike Zabeck
Publikováno v:
Pneumologie. 69
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::126e70a167901eb85dcbae9e19587584
https://doi.org/10.1055/s-0035-1544765
https://doi.org/10.1055/s-0035-1544765
Publikováno v:
British Journal of Cancer
This phase I study investigated the maximum tolerated dose and pharmacokinetics of a 3-weekly administration of BMS-188797, a paclitaxel derivate, at three dose levels (DLs) (80, 110 and 150 mg m(-2) DL), combined with cisplatin (standard dose 75 mg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93423bf264969a4e3ec4a409c5a99d70
http://europepmc.org/articles/PMC2361071
http://europepmc.org/articles/PMC2361071
Autor:
M.P. Lutz, E. van Cutsem, T. Langenbuch, H.-G. Mergenthaler, B. Genicot, U. Vanhoefer, R. Fuchs, Ö. Anak, P. Reichardt, P. Rougier, C.-H. Köhne, M. El-Serafi, B. Nordlinger, M. Lorenz, Jacques Wils, N. Frickhofen, C. Bokemeyer, H. Rückle-Lanz, L. Müller, R. Voigtmann
Publikováno v:
Journal of Clinical Oncology. 23:4856-4865
Purpose To demonstrate that adding irinotecan to a standard weekly schedule of high-dose, infusional fluorouracil (FU) and leucovorin (folinic acid [FA]) can prolong progression-free survival (PFS). Patients and Methods Four hundred thirty patients w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a0abc0d2d98b9b935d3600363565a5f7
https://doi.org/10.1200/jco.2005.05.546
https://doi.org/10.1200/jco.2005.05.546
Autor:
N. Frickhofen, V. Möbus
Publikováno v:
Der Onkologe. 8:1178-1186
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::06d552f7912640fbb260be970a91b9d8
https://doi.org/10.1007/s00761-002-0428-3
https://doi.org/10.1007/s00761-002-0428-3